| Literature DB >> 30631404 |
Hélcio Pedrosa Brito1, Igor Braga Ribeiro2, Diogo Turiani Hourneaux de Moura1, Wanderley Marques Bernardo1, Dalton Marques Chaves1, Rogério Kuga1, Ethan Dwane Maahs3, Robson Kiyoshi Ishida1, Eduardo Turiani Hourneaux de Moura1, Eduardo Guimarães Hourneaux de Moura1.
Abstract
AIM: To compare the diagnostic accuracy of video capsule endoscopy (VCE) and double-balloon enteroscopy (DBE) in cases of obscure gastrointestinal bleeding (OGIB) of vascular origin.Entities:
Keywords: Enteroscopy; Hemorrhage; Obscure hemorrhage; Small bowel bleeding; Upper gastrointestinal bleeding
Year: 2018 PMID: 30631404 PMCID: PMC6323498 DOI: 10.4253/wjge.v10.i12.400
Source DB: PubMed Journal: World J Gastrointest Endosc
QUADAS-2. Risk of bias in individual studies
| Was a consecutive or random sample of patients enrolled? | YES | UNCLEAR | UNCLEAR | YES | UNCLEAR | UNCLEAR | YES | YES | YES | YES | YES | YES | YES | YES | YES | UNCLEAR |
| Was a case-control design avoided? | YES | YES | NO | YES | YES | NO | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the study avoid inappropriate exclusions? | YES | YES | YES | YES | UNCLEAR | NO | YES | YES | YES | YES | YES | YES | YES | YES | YES | NO |
| Could the selection of patients have introduced bias? | LOW | MODERATE | HIGHT | LOW | HIGH | HIGH | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | HIGH |
| Are there concerns that the included patients do not match the review question? | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | HIGH |
| Were the index test results interpreted without knowledge of the results of the reference standard? | YES | NO | YES | NO | YES | NO | YES | UNCLEAR | UNCLEAR | UNCLEAR | YES | NO | YES | NO | NO | UNCLEAR |
| If a threshold was used, was it prespecified? Could the conduct or interpretation of the index test have introduced bias? | YES LOW | YES MODERATE | YES LOW | YES MODERATE | NO MODERATE | YES MODERATE | YES LOW | YES MODERATE | NO MODERATE | YES MODERATE | YES LOW | NO HIGH | YES LOW | YES MODERATE | YES MODERATE | YES MODERATE |
| Are there concerns that the index test, its conduct, or interpretation differ from the review question? | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | HIGH |
| Is the reference standard likely to correctly classify the target condition? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | NO | UNCLEAR |
| Were the reference standard results interpreted without knowledge of the results of the index test? | YES | NO | YES | NO | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | UNCLEAR |
| Could the reference standard, its conduct, or its interpretation have introduced bias? | LOW | MODERATE | LOW | MODERATE | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | HIGH | HIGH |
| Are there concerns that the target condition as defined by the reference standard does not match the review question? | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | LOW | HIGH | HIGH |
| Was there an appropriate interval between index test(s) and reference standard? | YES | NO | NO | NO | NO | NO | YES | YES | YES | YES | YES | YES | YES | NO | YES | UNCLEAR |
| Did all patients receive a reference standard? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did all patients receive the same reference standard? | NO | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Were all patients included in the analysis? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Could the patient flow have introduced bias? | MODERATE | LOW | LOW | LOW | LOW | MODERATE | LOW | LOW | LOW | LOW | LOW | LOW | LOW | MODERATE | LOW | LOW |
Figure 1Flow diagrams - PRISMA[36].
Figure 2Forrest plot: Double-balloon enteroscopy sensitivity per-lesion analysis.
Figure 3Forrest plot: Double-balloon enteroscopy specificity per-patient analysis.
Figure 4Forrest plot: Double-balloon enteroscopy positive likelihood ratio per-patient analysis.
Figure 5Forrest plot: Double-balloon enteroscopy negative likelihood ratio per-patient analysis.
Figure 6Summary receivers operating characteristic curve for double-balloon enteroscopy in per-patient analysis. sROC: Summary receiver operating characteristic.
Figure 7Summary receiver operating characteristic curve for video capsule endoscopy in per-patient analysis. sROC: Summary receiver operating characteristic.
Studies characteristics
| Fujimoto et al[ | 64 (38-93) | 45 M: 25 F: 20 | Prospective study | Pillcam (Given Imaging, Yoqneam, Israel). | EN-450P5 DBE diagnostic model and/or the EN-450T5 | CE: 12 h fast + 1 L sodium sulfate/sodium bicarbonate DBE: 72 h after CE in 36 pct | 72 h | 18/45 Angiodysplasia: 6 Varices: 2 jejunal | 18/36 |
| Hadithi et al[ | 63.2 (19-86) | 35 M:22 F: 13 | Prospective blinded study | Given M2A, Given Imaging Ltd., Yoqneam, Israel | Fuji Photo Optical Incorporated Company Fujinon Inc., Japan | CE: fast overnight after the ingestion of 1 L of sodium sulfate/sodium bicarbonate solution DBE: fast overnight after ingestion of 1 L clean prep. for the antegrade approach and bowel cleansing as for colonoscopy (4 L Klean prep) | 7 to 14 d | 21/35 AVM: 19 Fresh blood and clots: 5 | 28/35 AVM: 16 Fresh blood and clots: 2 |
| Hermans et al[ | 69 (18-91) | 146 M: 91 F: 55 | Retrospective observational study. | Olympus VC (Olympus EndoCapsule; Tokyo, Japan) and Pillcam VC (Covidien plc, Dublin, Ireland) | Fujinon Double-Balloon Enteroscopy System (Fujinon GMBH, Germany), EN-450T5 | CE: 2 L PEG in a single or split dose DBE: 1 L PEG divided into two doses to be used twice | 111 (1–1091) days | 105/134 Angiodysplasias: 70 active bleedings without visible focus : 35 | 93/146 Angiodysplasias: 19 |
| Holleran et al[ | 54 (16-90) | 246 M: 130 F: 116 | Retrospective comparative study | SB1 or SB2 pillcam (Given imaging, Yokneam, Israel) | Fujinon double-balloon enteroscope (EN-450P5/20, Fujinon, Inc., Saitama, Japan) | CE: No preparation was required other than an overnight fast. Anterograde DBE: overnight fast Retrograde DBE: PEG the day prior | NR* | 40/46 Angiodysplasia: 10 Active bleeding: 3 | 116/246 Angiodysplasias: 44 |
| Kaffes et al[ | 62 ± 18 | 60 | Prospective cohort study | M2A; Given Imaging Ltd, Yoqneam, Israel) | Fujinon | CE, DBE: fasting period of 8 h before the oral procedure and a bowel preparation with a sodium (Picoprep; Pharmatel, Thornleigh, Australia) | NR* | 45/60 Angiectasia:28 Red spots: 9 Blood: 8 | 45/60 Angioectasia: 21 Red spots: 9 Blood: 8 |
| Kalra, A et al[ | 66.6 ± 13.2 | 116 M:65 F: 51 | Retrospective review | Medtronic, Duluth, GA, the United States | Fujifilm Medical System, Stanford, CT, the United States | Retrograde DBE: bowel preparation the night before the procedure. | 1 yr | /69 | 29/69 AVM: 29 |
| Kamalaporn et al[ | 64.1 (34-83) | 195 M: 26 F:25 | Retrospective review | Given M2A CE system (Given Imaging Ltd, Israel) | Fujinon DBE system (Fuji Photo Optical Incorporated Company, Fujinon Inc., Japan) | CE: 2 to 4 L PEG and fasted overnight, at least 8 h before the procedure DBE: 4 L PEG and fasted overnight | 139 (40 to 335) d | 181/202 studies Angiodysplasia: 33 Bleeding: 22 | 56/56 Angiodysplasia: 36 Bleeding: 9 |
| Kameda et al[ | 62.4 (27-84) | 32 M: 13 F: 19 | Prospective single-blind trial | Pill Cam capsule (M2A, Given Imaging, Yoqneam, Israel) | DBE system (FujinonToshiba ES System, Saitama, Japan) | CE: fasting after midnight on the evening before the examination (minimum 8 h) DBE: overnight fasting and ingestion of 1 l of electrolyte lavage preparation (Niflec, Ajinomoto Pharma, Tokyo, Japan) in the morning. | 1-7 d | 29/32 Angiodysplasia: 8 bleeding: 6 | 21/32 Angiodysplasia: 7 bleeding: 6 |
| Li et al[ | 190 | Prospective study | M2A, Given Imaging, Ltd. (Yoqneam, Israel) | Fujinon EN-450P5/ 20 and EN-450P5/28 (Fujinon Inc., Saitama, Japan) | CE: 1 L of PEG electrolyte 12 h before the procedure Anterograde DBE: fasted for 8 h. Retrograde DBE: PEG electrolytes preparation 4 h before the examination | 5.8 d (1-18) | 165/190 AVM: 7 Fresh blood or clots: 8 | 34/51 AVM: 9 Bleeding: 0 Angioma: 4 | |
| Lin et al[ | 63.5 ± 22.7 (11-87) | 10 M:3 F:7 | Prospective study | Pill Cam SB capsule (Given Imaging, Yoqneam, Israel) | DBE: EN- 450P5 and the EN-450T5 | CE: fast overnight for 8-12 h Anterograde DBE: fasting for 6-8 h Retrograde DBE: bowel cleansing as in a colonoscopy. | 7 d | 9/10 Angiodysplasias: 3 Bleeding: 3 | 8/10 Angiodysplasias: 3 Varices: 1 Dieulafoy’s lesion: 1 |
| Maeda et al[ | 70 (30-92) | 89 M: 48 F: 41 | Retrospective analysis | PilCam SB® (SB1, SB2, or SB3) (Covidien, Irvine, CA, the United States). | (EN-450 T5/W or EN-580 T, Fujinon Inc., Saitama, Japan) | NR* | 24 h | 58/89 Angioectasia: 8 AVM : 3 Dieulafoy lesion: 9 Varices: 2 | 29/37 Angioectasia:8 AVM: 3 Dieulafoy lesion:6 Varice: 1 |
| Marmo R et al[ | 61.6 ± 16.2 | 193 M: 119 F: 74 | Prospective study | Pillcam SB | Fujinon Double-Balloon Enteroscopy System | Anterograde DBE: fasting period of 8 h Retrograde DBE: 4 L PEG-based preparation | 2 wk | 175/193 Vascular lesions: 74 Blood or clot: 34 | 132/193 Vascular lesions: 72 |
| Tian Min et al[ | 55.4 (23-78) | 62 M: 34 F:28 | Prospective study | Pill Cam SB capsule | EN-450P5 and the EN-450T5 (Fujinon) | CE: 2 L to 4 L PEG and fasted overnight Anterograde DBE: fasting for 6-8 h before the procedure. Retrograde DBE: bowel cleansing as in a colonoscopy. | 15 (4-60) d | 44/62 Angiodysplasia: 26 Bleeding: 26 | 48/62 Angiodysplasia: 27 Bleeding: 30 |
| Nakamura et al[ | 58.5 (25 ± 85) | 32 M: 21 F: 11 | Prospective and blinded | M2A, Given Imaging, | Fuji EN−450 T5/20 | CE: fluid diet for 12 h and observed a fasting period starting at midnight Anterograde DBE: fasted for 12 h Retrograde DBE: clear liquid diet on the day before the examination and PEG electrolyte lavage solution on the morning of the examination | 48 h | 19/32 Angiodysplasias: 4 Red spots: 2 | 12/28 Angiodysplasias: 2 Red spots: 2 |
| Rahmi et al[ | 67 ± 11 | 383 M: 114 F: 269 | Prospective, multicenter study | PillCam SB device | EN-450P5 and EN-450T5; Fujinon | CE: residue-free diet 2 d before VCE ingestion; 2 L PEG solution the night before the examination; patients then fasted overnight Anterograde DBE: No bowel preparation Retrograde DBE: 4 L of a PEG solution was given the day before the procedure | 4.1 ± 6.3 mo | 266/383 Angiodysplasia: 266 | 205/266 Angiodysplasia: 190 |
| Chu et al[ | 51.1 ± 17.1 | 121 M: 60 F: 61 | Study Cohorts | OMOM capsule endoscopic device (Jinshan Science and Technology Group Co., Ltd, Chongqing, China) | Fujinon EN-450P5/20 | CE: 2 L polyethylene glycol-based electrolyte solution 12 h prior to the test, followed by an overnight fast for bowel preparation fast Retrograde DBE: bowel preparation used for CE procedure the day before the examination | 1 wk | 115/121 Angiodysplasia: 86% Active bleeding: 6 | 29/46 Angiodysplasia: 9 |
| Zhang et al[ | 47.19 (16-78) | 88 M: 64 F: 24 | Prospective study | Pill Cam SB | Fuji DBE system | CE: 3 liters of PEG (2 liters at 10:00 pm the night before the procedure, and 1 L with the simethicone at 4:00 am on the morning of the procedure) Anterograde DBE: fast for 6-8 h Retrograde DBE: 2 L of PEG | NR | 53/88 MAV: 14 Hemangioma: 0 Diverticulum with a Bleeding: 1 | 52/88 MAV: 10 Hemangioma: 3 Diverticulum with a Bleeding: 7 |
M: Male; F: Female; SBB: Small bowel bleeding; PEG: Polyethylene glycol solution; AVM: Arteriovenous malformation; VC: Video capsule; NR: Not related; DBE: Double-balloon enteroscopy; VCE: Video capsule endoscope.
Figure 8Suggested management approach to overt and occult small-bowel bleeding after upper endoscopy and colonoscopy did not identify vascular bleeding origin. Positive test results should direct specific therapy. When video capsule endoscopy is contraindicated or unavailable, device-assisted endoscopy may serve as the initial test for small-bowel evaluation. VCE: Video capsule endoscopy; DAE: Device-assisted endoscopy; DBE: Double-balloon enteroscopy.